Northwest Biotherapeutics, Inc. (BST:NBYB)

Market Cap	311.92M
Revenue (ttm)	1.36M
Net Income (ttm)	-79.49M
Shares Out	n/a
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,215
Average Volume	22,959
Open	0.1990
Previous Close	0.2000
Day's Range	0.1990 - 0.2460
52-Week Range	0.1730 - 0.4500
Beta	n/a
RSI	55.68
Earnings Date	Aug 11, 2025

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types o...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 25
• Stock Exchange: Stuttgart Stock Exchange
• Ticker Symbol: NBYB

Financial Performance

In 2024, Northwest Biotherapeutics's revenue was $1.38 million, a decrease of -28.47% compared to the previous year's $1.93 million. Losses were -$85.19 million, 32.3% more than in 2023.

Financial numbers in USD